Infusion Options Recalls Vinblastine Infusions Due to Sterility Concerns
Infusion Options, Inc. is recalling Vinblastine infusions in New York due to a lack of assurance of sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves a lack of assurance of sterility in an intravenous medication, which poses a significant risk of serious injury or infection.
Plain-English summary
Infusion Options, Inc. is recalling Vinblastine 10.9 mg / 100 mL D5W IVPB and Vinblastine 10.8 mg / 100 mL D5W IVPB. The recall was initiated because of a lack of assurance of sterility for these products.
The affected products are prescription-only infusions distributed in New York. The recall covers all lots within their expiration dates.
Patients who have received these infusions should contact their healthcare provider for further instructions. Infusion Options, Inc. is the recalling firm located in Brooklyn, New York.
The recalled product
- Product
- VINBLASTINE 10.9 MG / 100 ML D5W IVPB; VINBLASTINE 10.8 MG / 100 ML D5W IVPB, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233
- Manufacturer
- Infusion Options, Inc.
- Category
- Drug — IV Infusion
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots within expiry
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 76 recalled by Infusion Options, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 76 products in this recall →Related recalls
Same manufacturer · Infusion Options, Inc.
See all →- SevereInfusion Options Recalls Calcium Glucunate IV Bags Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
- SevereInfusion Options Recalls Durvalumab Infusions Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
- SevereInfusion Options Recalls Rituximab Infusions Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
- SevereInfusion Options Recalls Fluorouracil Infusions Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
- SevereInfusion Options Recalls Velcade Syringes Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
Same hazard · sterility
See all →- SevereHeparin Sodium Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-10-28
- SevereFDA Recalls Testosterone Cypionate Vials Due to Sterility Concerns
FDA (Drugs) · 2026-10-28
- SevereHouston Rx LLC Recalls Tirzepatide/Niacinamide Vials Due to Sterility Concerns
FDA (Drugs) · 2026-10-21
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- HighDobutamine Injectable Medication Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-02-22
- SevereWalgreens Recalls Diphenhydramine Vials Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-01-28
- SevereFentanyl Infusion Solution Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2022-03-23
- HighFallon Wellness Pharmacy Recalls Hydroxocobalamin Injections Due to Sterility Concerns
FDA (Drugs) · 2015-05-20
- SevereFallon Wellness Pharmacy Recalls Methylcobalamin/B-Complex Injection Due to Sterility Concerns
FDA (Drugs) · 2015-05-20
- SeverePromise Pharmacy Recalls Leucine/Isoleucine/Valine Injection Due to Sterility Concerns
FDA (Drugs) · 2019-02-20